<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435381</url>
  </required_header>
  <id_info>
    <org_study_id>H-30334</org_study_id>
    <nct_id>NCT02435381</nct_id>
  </id_info>
  <brief_title>Carisbamate as a Potential Treatment for Alcohol Dependence</brief_title>
  <official_title>Carisbamate as a Potential Treatment for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of treatment with carisbamate compared&#xD;
      to treatment with placebo, on alcohol-induced stimulant and subjective effects in&#xD;
      non-treatment seeking alcohol-dependent human volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This within-subjects placebo-controlled experimental protocol will assess the effects of&#xD;
      carisbamate (600mg qd) on the positive subjective effects of alcohol in non-treatment-seeking&#xD;
      alcohol-dependent volunteers. Participants will receive study drug (carisbamate or placebo)&#xD;
      from days 2- 4. On day 4, study drug will be followed by alcohol (0.8g/kg; 16% by volume) and&#xD;
      a placebo beverage (1% by volume as a mask), both separated by 2 hours. Physiologic,&#xD;
      subjective effects and BAL will be obtained after the alcohol challenges. Participants will&#xD;
      be discharged on day 4 and asked to return a week later to repeat the study under the&#xD;
      alternate study drug condition (active carisbamate vs. placebo).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 30, 2013</completion_date>
  <primary_completion_date type="Actual">September 30, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Biphasic Alcohol Effects Scale (BAES) Scores</measure>
    <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages, stimulant ratings</time_frame>
    <description>The Biphasic Alcohol Effects Scale (BAES) is a self-report, unipolar adjective rating scale that is designed to measure both stimulant and sedative effects of alcohol. The BAES consists of 14 items that are rated on a eleven-point scale. The Sedation and Stimulation subscales are calculated by summing the following items (for the 14-point scale): Stimulation: = BAES3 + BAES4 + BAES5 + BAES11 + BAES12 + BAES13 +BAES14/ Sedation: = BAES1 + BAES2 + BAES6 + BAES7 + BAES8 + BAES9 + BAES10. Individuals are instructed to rate the extent to which drinking alcohol has produced these feelings in you at the present time from 0 (not at all) to 10 (extremely). Higher scores on the Sedative Subscale represent extreme sedation (0 not at all sedated - 70 extremely sedated). Higher scores on the Stimulant Subscale represent extreme stimulation (0 not at all stimulated - 70 extremely stimulated). Scale scores are calculated as the sum of respective stimulant and sedative effects items.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Alcohol Urge Questionnaire (AUQ) Scores</measure>
    <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
    <description>The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). Drinking refers to various types of alcohol, including beer, wine and liquor. The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from &quot;0-strongly disagree&quot; to &quot;6- strongly agree.&quot; Item scores were averaged and the total score also ranges from 0-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Positive and Negative Affect Schedule (PANAS) Scores</measure>
    <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
    <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Range between 10 and 50 points. Higher positive affect scores indicated a better outcome, while lower negative affect scores indicated a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MEAN DRUG EFFECTS QUESTIONNAIRE (DEQ) SCORES</measure>
    <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
    <description>Self-reported subjective drug effects questionnaire evaluated whether a respondent was currently affected by doses of alcohol. Participants completed VAS at regular intervals after ingesting active alcohol (0.8g/kg; 16% by volume) or placebo (1% by volume as a mask). The questionnaire assessed the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, &quot;Dislike Drug&quot;, and &quot;Want More&quot; subscales are reported.Each item is rated on a 100-point scale of 1 (not at all) to 100 (extremely). 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologic Effects of Carisbamate: Mean Systolic and Diastolic Blood Pressure</measure>
    <time_frame>15, 30 and 60 minutes after alcohol (0.8 mg/kg;16% by volume) consumption</time_frame>
    <description>systolic and diastolic blood pressure will be monitored after consuming carisbamate and alcohol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic Effects of Carisbamate: Mean Heart Rate</measure>
    <time_frame>15, 30 and 60 minutes after alcohol (0.8 mg/kg;16% by volume) consumption</time_frame>
    <description>pulse will be monitored after consuming carisbamate and alcohol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo from days 2- 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carisbamate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive carisbamate 600mg qd from days 2- 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisbamate</intervention_name>
    <description>600mg Orally on days 2-4</description>
    <arm_group_label>Carisbamate</arm_group_label>
    <other_name>YKP 509</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment only</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be an English-speaking volunteer who is not seeking treatment at the time of the study&#xD;
&#xD;
          2. Be between 18-55 years of age&#xD;
&#xD;
          3. Meet DSM-IV TR criteria for alcohol abuse; participants may or may not meet criteria&#xD;
             for nicotine dependence. Nicotine dependence is allowed but not required because most&#xD;
             alcohol users smoke cigarettes.&#xD;
&#xD;
          4. Have a self-reported history of using alcohol.&#xD;
&#xD;
          5. Have vital signs as follows: resting pulse must be &lt; 90 bpm and the blood pressure&#xD;
             must be &lt; 150 mmHg systolic and &lt; 90 mmHg diastolic.&#xD;
&#xD;
          6. Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits&#xD;
             with the following exceptions:&#xD;
&#xD;
               -  liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) &lt; 3 x&#xD;
                  the upper limit of normal, and b) kidney function tests (creatinine and BUN)&#xD;
                  within normal limits&#xD;
&#xD;
          7. Have a baseline EKG that demonstrates clinically normal sinus rhythm, clinically&#xD;
             normal conduction, and no clinically significant arrhythmias&#xD;
&#xD;
          8. Have a medical history and brief physical examination demonstrating no clinically&#xD;
             significant contraindications for study participation, in the judgment of the&#xD;
             admitting physician and the principal investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meet DSM IV TR criteria for dependence on drugs other than alcohol or nicotine.&#xD;
&#xD;
          2. Have any history or evidence suggestive of seizure disorder or brain injury&#xD;
&#xD;
          3. Have any previous medically adverse reaction to alcohol, including loss of&#xD;
             consciousness, chest pain, or epileptic seizure&#xD;
&#xD;
          4. Have neurological or psychiatric disorders, such as:&#xD;
&#xD;
               -  psychosis, bipolar illness or major depression as assessed by SCID&#xD;
&#xD;
               -  organic brain disease or dementia assessed by clinical interview&#xD;
&#xD;
               -  history of any psychiatric disorder which would require ongoing treatment or&#xD;
                  which would make study compliance difficult&#xD;
&#xD;
               -  history of suicide attempts within the past year and/or current suicidal&#xD;
                  ideation/plan&#xD;
&#xD;
          5. Have evidence of clinically significant heart disease or hypertension, as determined&#xD;
             by the PI&#xD;
&#xD;
          6. Have evidence of untreated or unstable medical illness including: neuroendocrine,&#xD;
             autoimmune, renal, hepatic, or active infectious disease&#xD;
&#xD;
          7. Have symptomatic HIV or are taking antiretroviral medication&#xD;
&#xD;
          8. Be pregnant or nursing. Other females must either be unable to conceive (i.e.,&#xD;
             surgically sterilized, sterile, or post-menopausal) or be using a reliable form of&#xD;
             contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or&#xD;
             spermicide). All females must provide negative pregnancy urine tests before study&#xD;
             entry, upon hospital admission, and at the end of study participation&#xD;
&#xD;
          9. Have any other illness, condition, or use of psychotropic medications, which in the&#xD;
             opinion of the PI and/or the admitting physician would preclude safe and/or successful&#xD;
             completion of the study.&#xD;
&#xD;
         10. Currently seeking help for alcohol dependence.&#xD;
&#xD;
         11. Subjects with or prone to clinically significant alcohol withdrawal.&#xD;
&#xD;
         12. More than thirty days of abstinence from alcohol in the ninety days prior to&#xD;
             enrollment.&#xD;
&#xD;
         13. A history of major alcohol-related medical complications requiring hospitalization&#xD;
             (i.e. pancreatitis).&#xD;
&#xD;
         14. Contraindication(s) to take the study medication such as renal or hepatic impairment,&#xD;
             nephrolithiasis, congenital metabolic disorders or history of seizures.&#xD;
             Moderate-to-severe renal impairment defined as creatinine clearance less than 30&#xD;
             mL/min.&#xD;
&#xD;
         15. Use of inhibitors/substrates for renal cationic transporters, or medications&#xD;
             contraindicated with ethanol.&#xD;
&#xD;
         16. A history of violence or aggression, assessed as part of the clinical interview at&#xD;
             screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Newton, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Christopher Verrico</investigator_full_name>
    <investigator_title>Assistant Professor, Psychiatry Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02435381/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was a crossover design, double-blind, placebo controlled, 8 week clinical trail.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Carisbamate</title>
          <description>Participants received placebo from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition (active carisbamate)</description>
        </group>
        <group group_id="P2">
          <title>Carisbamate First, Then Placebo</title>
          <description>Participants received carisbamate from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition (placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Carisbamate</title>
          <description>This within-subjects study included two treatment arms (placebo and carisbamate); 8 subjects completed both study arms.&#xD;
Participants received placebo on study days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study procedures under the alternate study drug condition (active carisbamate)&#xD;
Placebo: 0mg orally on days 2-4 Carisbamate: 600mg orally on days 2-4</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>U.S. Veteran</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Biphasic Alcohol Effects Scale (BAES) Scores</title>
        <description>The Biphasic Alcohol Effects Scale (BAES) is a self-report, unipolar adjective rating scale that is designed to measure both stimulant and sedative effects of alcohol. The BAES consists of 14 items that are rated on a eleven-point scale. The Sedation and Stimulation subscales are calculated by summing the following items (for the 14-point scale): Stimulation: = BAES3 + BAES4 + BAES5 + BAES11 + BAES12 + BAES13 +BAES14/ Sedation: = BAES1 + BAES2 + BAES6 + BAES7 + BAES8 + BAES9 + BAES10. Individuals are instructed to rate the extent to which drinking alcohol has produced these feelings in you at the present time from 0 (not at all) to 10 (extremely). Higher scores on the Sedative Subscale represent extreme sedation (0 not at all sedated - 70 extremely sedated). Higher scores on the Stimulant Subscale represent extreme stimulation (0 not at all stimulated - 70 extremely stimulated). Scale scores are calculated as the sum of respective stimulant and sedative effects items.</description>
        <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages, stimulant ratings</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Alcohol Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate + Alcohol Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Placebo Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O4">
            <title>Carisbamate + Placebo Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Biphasic Alcohol Effects Scale (BAES) Scores</title>
          <description>The Biphasic Alcohol Effects Scale (BAES) is a self-report, unipolar adjective rating scale that is designed to measure both stimulant and sedative effects of alcohol. The BAES consists of 14 items that are rated on a eleven-point scale. The Sedation and Stimulation subscales are calculated by summing the following items (for the 14-point scale): Stimulation: = BAES3 + BAES4 + BAES5 + BAES11 + BAES12 + BAES13 +BAES14/ Sedation: = BAES1 + BAES2 + BAES6 + BAES7 + BAES8 + BAES9 + BAES10. Individuals are instructed to rate the extent to which drinking alcohol has produced these feelings in you at the present time from 0 (not at all) to 10 (extremely). Higher scores on the Sedative Subscale represent extreme sedation (0 not at all sedated - 70 extremely sedated). Higher scores on the Stimulant Subscale represent extreme stimulation (0 not at all stimulated - 70 extremely stimulated). Scale scores are calculated as the sum of respective stimulant and sedative effects items.</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'BAES Stimulant Subscale' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="5.8"/>
                    <measurement group_id="O2" value="32.4" spread="4.1"/>
                    <measurement group_id="O3" value="23.0" spread="6.9"/>
                    <measurement group_id="O4" value="21.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'BAES Stimulant Subscale' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="4.5"/>
                    <measurement group_id="O2" value="32.5" spread="4.1"/>
                    <measurement group_id="O3" value="26.0" spread="6.6"/>
                    <measurement group_id="O4" value="18.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'BAES Stimulant Subscale' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="6.2"/>
                    <measurement group_id="O2" value="29.0" spread="7.2"/>
                    <measurement group_id="O3" value="20.6" spread="6.0"/>
                    <measurement group_id="O4" value="20.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'BAES Sedative Subscale' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="4.9"/>
                    <measurement group_id="O2" value="16.8" spread="5.1"/>
                    <measurement group_id="O3" value="4.9" spread="2.6"/>
                    <measurement group_id="O4" value="11.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'BAES Sedative Subscale' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="6.1"/>
                    <measurement group_id="O2" value="20.4" spread="6.5"/>
                    <measurement group_id="O3" value="7.6" spread="3.8"/>
                    <measurement group_id="O4" value="8.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'BAES Sedative Subscale' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="5.9"/>
                    <measurement group_id="O2" value="20.1" spread="7.1"/>
                    <measurement group_id="O3" value="5.3" spread="3.0"/>
                    <measurement group_id="O4" value="9.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Alcohol Urge Questionnaire (AUQ) Scores</title>
        <description>The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). Drinking refers to various types of alcohol, including beer, wine and liquor. The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from &quot;0-strongly disagree&quot; to &quot;6- strongly agree.&quot; Item scores were averaged and the total score also ranges from 0-6.</description>
        <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Alcohol Beverage</title>
            <description>Participants will receive placebo from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition (active carisbamate)&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate + Alcohol Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition ( placebo).&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Placebo Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O4">
            <title>Carisbamate + Placebo Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Alcohol Urge Questionnaire (AUQ) Scores</title>
          <description>The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). Drinking refers to various types of alcohol, including beer, wine and liquor. The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from &quot;0-strongly disagree&quot; to &quot;6- strongly agree.&quot; Item scores were averaged and the total score also ranges from 0-6.</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'AUQ' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.4"/>
                    <measurement group_id="O2" value="3.5" spread="0.5"/>
                    <measurement group_id="O3" value="3.1" spread="0.4"/>
                    <measurement group_id="O4" value="3.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'AUQ' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.4"/>
                    <measurement group_id="O2" value="3.9" spread="0.5"/>
                    <measurement group_id="O3" value="2.9" spread="0.5"/>
                    <measurement group_id="O4" value="3.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'AUQ' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.5"/>
                    <measurement group_id="O2" value="3.4" spread="0.6"/>
                    <measurement group_id="O3" value="3.1" spread="0.5"/>
                    <measurement group_id="O4" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Positive and Negative Affect Schedule (PANAS) Scores</title>
        <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Range between 10 and 50 points. Higher positive affect scores indicated a better outcome, while lower negative affect scores indicated a better outcome.</description>
        <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Alcohol Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate + Alcohol Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Placebo Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O4">
            <title>Carisbamate + Placebo Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Positive and Negative Affect Schedule (PANAS) Scores</title>
          <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Range between 10 and 50 points. Higher positive affect scores indicated a better outcome, while lower negative affect scores indicated a better outcome.</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'PANAS, Positive' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="3.4"/>
                    <measurement group_id="O2" value="27.5" spread="3.0"/>
                    <measurement group_id="O3" value="27.5" spread="3.3"/>
                    <measurement group_id="O4" value="26.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'PANAS, Positive' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="3.2"/>
                    <measurement group_id="O2" value="29.3" spread="3.5"/>
                    <measurement group_id="O3" value="27.9" spread="2.8"/>
                    <measurement group_id="O4" value="26.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'PANAS, Positive' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="2.2"/>
                    <measurement group_id="O2" value="27.6" spread="2.9"/>
                    <measurement group_id="O3" value="29.3" spread="2.9"/>
                    <measurement group_id="O4" value="28.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'PANAS, Negative' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="2.0"/>
                    <measurement group_id="O2" value="13.0" spread="1.7"/>
                    <measurement group_id="O3" value="12.0" spread="1.2"/>
                    <measurement group_id="O4" value="13.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'PANAS, Negative' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="2.0"/>
                    <measurement group_id="O2" value="13.9" spread="1.6"/>
                    <measurement group_id="O3" value="13.0" spread="2.5"/>
                    <measurement group_id="O4" value="14.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'PANAS, Negative' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="2.5"/>
                    <measurement group_id="O2" value="14.1" spread="2.6"/>
                    <measurement group_id="O3" value="12.9" spread="2.2"/>
                    <measurement group_id="O4" value="15.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MEAN DRUG EFFECTS QUESTIONNAIRE (DEQ) SCORES</title>
        <description>Self-reported subjective drug effects questionnaire evaluated whether a respondent was currently affected by doses of alcohol. Participants completed VAS at regular intervals after ingesting active alcohol (0.8g/kg; 16% by volume) or placebo (1% by volume as a mask). The questionnaire assessed the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, &quot;Dislike Drug&quot;, and &quot;Want More&quot; subscales are reported.Each item is rated on a 100-point scale of 1 (not at all) to 100 (extremely). 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
        <time_frame>15, 30 and 60 minutes after consumption of placebo (1% alcohol by volume) and alcohol (0.8g/kg; 16% by volume) beverages.</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Alcohol Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate + Alcohol Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Placebo Beverage</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O4">
            <title>Carisbamate + Placebo Beverage</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>MEAN DRUG EFFECTS QUESTIONNAIRE (DEQ) SCORES</title>
          <description>Self-reported subjective drug effects questionnaire evaluated whether a respondent was currently affected by doses of alcohol. Participants completed VAS at regular intervals after ingesting active alcohol (0.8g/kg; 16% by volume) or placebo (1% by volume as a mask). The questionnaire assessed the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, &quot;Dislike Drug&quot;, and &quot;Want More&quot; subscales are reported.Each item is rated on a 100-point scale of 1 (not at all) to 100 (extremely). 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo (1% alcohol by volume) and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol and placebo beverage, for the 8 subjects that completed both study arms.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'FEEL' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="12.3"/>
                    <measurement group_id="O2" value="53.2" spread="14.4"/>
                    <measurement group_id="O3" value="14.0" spread="12.3"/>
                    <measurement group_id="O4" value="23.6" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'FEEL' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="11.6"/>
                    <measurement group_id="O2" value="53.5" spread="14.2"/>
                    <measurement group_id="O3" value="10.9" spread="9.3"/>
                    <measurement group_id="O4" value="16.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'FEEL' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="12.8"/>
                    <measurement group_id="O2" value="42.6" spread="13.5"/>
                    <measurement group_id="O3" value="11.4" spread="10.1"/>
                    <measurement group_id="O4" value="16.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'LIKE' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="13.5"/>
                    <measurement group_id="O2" value="54.0" spread="13.6"/>
                    <measurement group_id="O3" value="23.1" spread="10.2"/>
                    <measurement group_id="O4" value="33.4" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'LIKE' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="13.2"/>
                    <measurement group_id="O2" value="47.8" spread="15.2"/>
                    <measurement group_id="O3" value="27.4" spread="13.4"/>
                    <measurement group_id="O4" value="17.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'LIKE' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" spread="13.1"/>
                    <measurement group_id="O2" value="33.8" spread="11.8"/>
                    <measurement group_id="O3" value="18.6" spread="11.0"/>
                    <measurement group_id="O4" value="24.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'DISLIKE' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="8.9"/>
                    <measurement group_id="O2" value="22.8" spread="14.1"/>
                    <measurement group_id="O3" value="18.9" spread="12.3"/>
                    <measurement group_id="O4" value="24.1" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'DISLIKE' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="7.6"/>
                    <measurement group_id="O2" value="21.9" spread="14.3"/>
                    <measurement group_id="O3" value="22.4" spread="14.1"/>
                    <measurement group_id="O4" value="15.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'DISLIKE' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="12.1"/>
                    <measurement group_id="O2" value="18.0" spread="11.0"/>
                    <measurement group_id="O3" value="22.3" spread="14.1"/>
                    <measurement group_id="O4" value="35.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'HIGH' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="10.9"/>
                    <measurement group_id="O2" value="53.8" spread="14.4"/>
                    <measurement group_id="O3" value="8.8" spread="6.7"/>
                    <measurement group_id="O4" value="31.6" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'HIGH' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="10.6"/>
                    <measurement group_id="O2" value="52.1" spread="13.6"/>
                    <measurement group_id="O3" value="10.3" spread="8.6"/>
                    <measurement group_id="O4" value="13.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'HIGH' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" spread="13.5"/>
                    <measurement group_id="O2" value="46.9" spread="14.3"/>
                    <measurement group_id="O3" value="1.9" spread="1.3"/>
                    <measurement group_id="O4" value="10.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'WANT MORE' +15 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="14.3"/>
                    <measurement group_id="O2" value="50.5" spread="14.0"/>
                    <measurement group_id="O3" value="24.1" spread="12.3"/>
                    <measurement group_id="O4" value="28.9" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'WANT MORE' +30 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="14.5"/>
                    <measurement group_id="O2" value="56.3" spread="15.0"/>
                    <measurement group_id="O3" value="30.1" spread="12.4"/>
                    <measurement group_id="O4" value="23.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'WANT MORE' +60 minutes after alcohol and placebo beverage consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="12.6"/>
                    <measurement group_id="O2" value="50.0" spread="15.7"/>
                    <measurement group_id="O3" value="28.3" spread="11.9"/>
                    <measurement group_id="O4" value="15.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physiologic Effects of Carisbamate: Mean Systolic and Diastolic Blood Pressure</title>
        <description>systolic and diastolic blood pressure will be monitored after consuming carisbamate and alcohol</description>
        <time_frame>15, 30 and 60 minutes after alcohol (0.8 mg/kg;16% by volume) consumption</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol only, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will receive placebo from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition (active carisbamate)&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4. Participants were discharged on day 4 and asked to return a week later to repeat the study under the alternate study drug condition ( placebo).&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects of Carisbamate: Mean Systolic and Diastolic Blood Pressure</title>
          <description>systolic and diastolic blood pressure will be monitored after consuming carisbamate and alcohol</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol only, for the 8 subjects that completed both study arms.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'Systolic BP' + 15 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.4" spread="7.1"/>
                    <measurement group_id="O2" value="140.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Systolic BP' + 30 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.0" spread="8.0"/>
                    <measurement group_id="O2" value="137.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Systolic BP' + 60 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.8" spread="10.5"/>
                    <measurement group_id="O2" value="134.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Diastolic BP' + 15 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="4.4"/>
                    <measurement group_id="O2" value="87.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Diastolic BP' + 30 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" spread="4.2"/>
                    <measurement group_id="O2" value="84.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Diastolic BP' + 60 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="3.9"/>
                    <measurement group_id="O2" value="79.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physiologic Effects of Carisbamate: Mean Heart Rate</title>
        <description>pulse will be monitored after consuming carisbamate and alcohol</description>
        <time_frame>15, 30 and 60 minutes after alcohol (0.8 mg/kg;16% by volume) consumption</time_frame>
        <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol only, for the 8 subjects that completed both study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
          </group>
          <group group_id="O2">
            <title>Carisbamate</title>
            <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects of Carisbamate: Mean Heart Rate</title>
          <description>pulse will be monitored after consuming carisbamate and alcohol</description>
          <population>This within-subjects study included 2 treatment arms (placebo &amp; carisbamate), during both arms subjects completed study procedures twice, once after consuming placebo and once after consuming alcohol (0.8g/kg; 16% by volume). The data here represent the means, following consumption of alcohol only, for the 8 subjects that completed both study arms.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>'Pulse' + 15 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="4.0"/>
                    <measurement group_id="O2" value="86.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Pulse' + 30 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="2.0"/>
                    <measurement group_id="O2" value="90.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>'Pulse' + 60 minutes after alcohol (0.8g/kg; 16% by volume) consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="2.5"/>
                    <measurement group_id="O2" value="91.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was assessed over the 4 week active enrollment period on each condition (active carisbamate vs. placebo), up to 8 weeks following active enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo First, Then Carisbamate</title>
          <description>Participants will receive placebo from days 2- 4.&#xD;
Placebo: Placebo treatment only</description>
        </group>
        <group group_id="E2">
          <title>Carisbamate First, Then Placebo</title>
          <description>Participants will receive carisbamate 600mg qd from days 2- 4.&#xD;
Carisbamate: 600mg Orally on days 2-4</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator shall have the right to publish or otherwise publicly disclose information gained in the course of this Agreement. Investigator agrees to submit to Company copies of manuscripts, posters, slides, or abstracts that are intended for presentation or publication and that contain the results of the performance of this Agreement not less than 30 days before submission of manuscripts for publications or presentations of slides and posters, or 10 days prior to abstract submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher D. Verrico Ph.D.</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-791-1414 ext 26020</phone>
      <email>Cverrico@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

